Zoetis (ZTS) Given a $85.00 Price Target at Cantor Fitzgerald

Zoetis (NYSE:ZTS) has been given a $85.00 price objective by equities researchers at Cantor Fitzgerald in a report issued on Thursday. The firm currently has a “buy” rating on the stock. Cantor Fitzgerald’s target price points to a potential upside of 12.75% from the stock’s previous close.

ZTS has been the topic of a number of other research reports. BMO Capital Markets set a $65.00 target price on Zoetis and gave the company a “hold” rating in a report on Wednesday, October 25th. Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. BidaskClub lowered Zoetis from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Cowen set a $80.00 target price on Zoetis and gave the company a “buy” rating in a report on Friday, November 17th. Finally, Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 target price on the stock in a report on Wednesday, November 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $71.94.

Zoetis (ZTS) traded up $0.80 on Thursday, reaching $75.39. The company’s stock had a trading volume of 1,902,500 shares, compared to its average volume of 1,950,000. The firm has a market cap of $36,740.00, a price-to-earnings ratio of 39.68, a P/E/G ratio of 1.88 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a 12-month low of $52.00 and a 12-month high of $75.69.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.52 EPS. equities research analysts expect that Zoetis will post 2.37 EPS for the current year.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Zoetis by 3.9% during the 2nd quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after purchasing an additional 1,412,829 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock worth $2,099,379,000 after purchasing an additional 910,265 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Zoetis by 1.5% during the 3rd quarter. Janus Henderson Group PLC now owns 5,893,853 shares of the company’s stock worth $375,792,000 after purchasing an additional 84,767 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Zoetis by 1.2% during the 2nd quarter. Northern Trust Corp now owns 5,533,313 shares of the company’s stock worth $345,168,000 after purchasing an additional 63,849 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Zoetis by 1.5% during the 3rd quarter. Legal & General Group Plc now owns 2,400,106 shares of the company’s stock worth $153,025,000 after purchasing an additional 34,747 shares in the last quarter. 93.19% of the stock is currently owned by institutional investors.

WARNING: This article was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.themarketsdaily.com/2018/01/14/zoetis-zts-given-a-85-00-price-target-at-cantor-fitzgerald.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply